22:43 , Nov 15, 2018 |  BC Innovations  |  Tools & Techniques

Benchtop manufacturing gets smaller

MIT scientists continue to break new ground in benchtop manufacturing systems for biologics. Published in...
11:33 , Nov 13, 2018 |  BC Extra  |  Financial News

Hillhouse, Quan lead $93M series B for immuno-oncology play NextCure

NextCure Inc. (Beltsville, Md.) raised $93 million in a series B round led by new investors Hillhouse Capital Management and Quan Capital to fund development of its two lead immuno-oncology candidates. PD-1 pioneer Lieping Chen...
17:57 , Nov 9, 2018 |  BC Week In Review  |  Company News

NextCure, Lilly partner to find new immuno-oncology targets

PD-1 pioneer Lieping Chen's NextCure Inc. (Beltsville, Md.) partnered with Eli Lilly and Co. (NYSE:LLY) to use the biotech's FIND-IO platform to discover immuno-oncology targets. FIND-IO identifies new targets on immune-suppressive macrophages, dendritic cells and...
21:44 , Nov 5, 2018 |  BC Extra  |  Company News

NextCure, Lilly partner to find new immuno-oncology targets

PD-1 pioneer Lieping Chen's NextCure Inc. (Beltsville, Md.) partnered with Eli Lilly and Co. (NYSE:LLY) to use the biotech's FIND-IO platform to discover immuno-oncology targets. FIND-IO identifies new targets on immune-suppressive macrophages, dendritic cells and...
01:37 , Aug 10, 2018 |  BC Innovations  |  Finance

Super-sized ambitions

A trend toward super-sized initial financings is attracting a new set of deep-pocketed investors to the early stage space. These new players are making earlier commitments with hopes of guaranteeing larger ownership positions at an...
23:35 , Apr 5, 2018 |  BC Extra  |  Company News

Management Tracks: CRISPR, Moderna

Gene editing company CRISPR Therapeutics AG (NASDAQ:CRSP) hired Steve Caffé as head of regulatory affairs. Caffé was SVP at Ra Pharmaceuticals Inc. (NASDAQ:RARX). mRNA company Moderna Therapeutics Inc. (Cambridge, Mass.) hired Megan Pace as chief...
18:36 , Jan 11, 2018 |  BC Innovations  |  Emerging Company Profile

Next, after T cells

PD-1 pioneer Lieping Chen is solving some of the unanswered questions from that breakthrough with his new company, NextCure Inc. The idea is to use myeloid cell factors to boost the effectiveness of other T...
01:10 , Sep 16, 2017 |  BioCentury  |  Finance

Local leverage

What began as a fund designed to provide Eli Lilly and Co. access to innovation in China has evolved into an independent VC with a focus on innovative Chinese healthcare companies and U.S. biotechs looking...
07:00 , Oct 24, 2016 |  BioCentury  |  Finance

Sofinnova steps up

With fewer crossover investors participating in its private biotech financings, Sofinnova Ventures has raised a new $650 million fund that will allow it to invest more capital per company to see them through key milestones....
08:00 , Jan 25, 2016 |  BioCentury  |  Strategy

Preclinical hunting ground

With a new dedicated preclinical investment initiative, Pfizer Inc. is hoping to more systematically evaluate and invest in the large number of opportunities that fall between its academic translational research collaborations and its venture arm....